**Supplementary References**

S1. Zetterberg H, Blennow K. From cerebrospinal fluid to blood: The third wave of fluid biomarkers for Alzheimer's Disease. J Alzheimer's Dis. 2018;64(s1):S271-S279. doi:10.3233/JAD-179926

S2. Lin J, Li J, Huang B, et al. Exosomes: Novel biomarkers for clinical diagnosis. Sci World J. 2015;657086. doi:10.1155/2015/657086

S3. Saeedi S, Israel S, Nagy C, Turecki G. The emerging role of exosomes in mental disorders. Transl Psychiatry. 2019;9(1). doi:10.1038/s41398-019-0459-9

S4. Jiang C, Hopfner F, Hopfner F, et al. Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020;91(7):720-729. doi:10.1136/jnnp-2019-322588

S5. Shepheard SR, Wuu J, Cardoso SM, et al. Urinary P75 ECD a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137-1143. doi:10.1212/WNL.0000000000003741

S6. González-Sánchez M, Bartolome F, Antequera D, et al. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020:102834. doi:10.1016/j.ebiom.2020.102834

S7. Kan CW, Tobos CI, Rissin DM, et al. Digital enzyme-linked immunosorbent assays with sub-attomolar detection limits based on low numbers of capture beads combined with high efficiency bead analysis. Lab Chip. 2020;20(12):2122-2135. doi:10.1039/d0lc00267d

S8. Yao NY, Braedersz CP, Lin YC, Kasza KE, MacKintosh FC, Weitz DA. Elasticity in lonically cross-linked neurofilament networks. Biophys J. 2010;98(10):2147-2153. doi:10.1016/j.bpj.2010.01.062

S9. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116-126. doi:10.1002/ana.24052

S10. Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329-1336. doi:10.1212/WNL.0000000000003154

S11. Rojas JC, Bang J, Lobach I V., et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018;90(4):E273-E281. doi:10.1212/WNL.0000000000004859

S12. Steinacker P, Anderl-Straub S, Diehl-Schmid J, et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018;91(15):E1390-E1401. doi:10.1212/WNL.0000000000006318

S13. Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623-636. doi:10.1002/acn3.325

S14. Donker Kaat L, Meeter LH, Chiu WZ, et al. Serum neurofilament light chain in progressive supranuclear palsy. Park Relat Disord. 2018;56:98-101. doi:10.1016/j.parkreldis.2018.06.018

S15. Meeter LHH, Steketee RME, Salkovic D, et al. Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. J Neurol Neurosurg Psychiatry. 2019;90(9):997-1004. doi:10.1136/jnnp-2018-319784

S16. Steinacker P, Semler E, Anderl-Straub S, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017;88(10):961-969. doi:10.1212/WNL.0000000000003688

S17. Bridel C, Van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol. 2019;76(9):1035-1048. doi:10.1001/jamaneurol.2019.1534

S18. Katisko K, Cajanus A, Jääskeläinen O, et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol. 2020;267(1):162-167. doi:10.1007/s00415-019-09567-8

S19. van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103-1111. doi:10.1016/S1474-4422(19)30354-0

S20. Winter B, Guenther R, Ludolph AC, Hermann A, Otto M, Wurster CD. Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. J Neurol Neurosurg Psychiatry. 2019;90(9):1068-1069. doi:10.1136/jnnp-2018-320033

S21. Wilke C, Pujol-Calderón F, Barro C, et al. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: A comparison of three analytical approaches. Clin Chem Lab Med. 2019;57(10). doi:10.1515/cclm-2019-0015

S22. Remnestål J, Öijerstedt L, Ullgren A, et al. Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Transl Neurodegener. 2020;9(1). doi:10.1186/s40035-020-00198-y

S23. Gendron TF, Daughrity LM, Heckman MG, et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82(1):139-146. doi:10.1002/ana.24980

S24. Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109-119. doi:10.1056/NEJMoa2003715

S25. Vatsavayai SC, Jin Yoon S, Gardner RC, et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139(12):3202-3216. doi:10.1093/brain/aww250

S26. Rascovsky K, Grossman M. Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration. Int Rev Psychiatry. 2013;25(2):145. doi:10.3109/09540261.2013.763341

S27. Ahmed RM, Latheef S, Bartley L, et al. Eating behavior in frontotemporal dementia. Neurology. 2015;85(15):1310-1317. doi:10.1212/WNL.0000000000002018

S28. Ahmed RM, Irish M, Henning E, et al. Assessment of eating behavior disturbance and associated neural networks in frontotemporal dementia. JAMA Neurol. 2016;73(3):282. doi:10.1001/jamaneurol.2015.4478

S29. Ikeda M, Brown J, Holland AJ, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;73(4):371-376. doi:10.1136/jnnp.73.4.371

S30. Ahmed RM, Irish M, Kam J, et al. Quantifying the eating abnormalities in frontotemporal dementia. JAMA Neurol. 2014;71(12):1540-1546. doi:10.1001/jamaneurol.2014.1931

S31. Ahmed RM, Landin-Romero R, Collet TH, et al. Energy expenditure in frontotemporal dementia: A behavioural and imaging study. Brain. Published online 2017. doi:10.1093/brain/aww263

S32. Piguet O, Petersén Å, Yin Ka Lam B, et al. Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol. 2011;69(2):312-319. doi:10.1002/ana.22244

S33. Bocchetta M, Gordon E, Manning E, et al. Detailed volumetric analysis of the hypothalamus in behavioral variant frontotemporal dementia. J Neurol. 2015;262(12):2635-2642. doi:10.1007/s00415-015-7885-2

S34. Vercruysse P, Vieau D, Blum D, Petersén Å, Dupuis L. Hypothalamic alterations in neurodegenerative diseases and their relation to abnormal energy metabolism. Front Mol Neurosci. 2018;11. doi:10.3389/fnmol.2018.00002

S35. Woolley JD, Khan BK, Natesan A, et al. Satiety-related hormonal dysregulation in behavioral variant frontotemporal dementia. Neurology. 2014;82(6):512-520. doi:10.1212/WNL.0000000000000106

S36. Ahmed RM, Phan K, Highton-Williamson E, et al. Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Ann Clin Transl Neurol. 2019;6(3):486-495. doi:10.1002/acn3.721

S37. Zanardini R, Benussi L, Fostinelli S, et al. Serum C-peptide, visfatin, resistin, and ghrelin are altered in sporadic and grn-associated frontotemporal lobar degeneration. J Alzheimer's Dis. 2018;61(3):1053-1060. doi:10.3233/JAD-170747

S38. Liguori C, Romigi A, Mercuri NB, et al. Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. J Neurol. 2014;261(9):1832-1836. doi:10.1007/s00415-014-7455-z

S39. Çoban A, Bilgiç B, Lohmann E, et al. Reduced orexin-a levels in frontotemporal dementia: Possible association with sleep disturbance. Am J Alzheimers Dis Other Demen. 2013;28(6):606-611. doi:10.1177/1533317513494453

S40. Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD, Garcia PA, Rabinovici GD, Coppola G, Geschwind DH, Petrucelli L, Miller BL, Seeley WW. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016 Dec;139(Pt 12):3202-3216. doi: 10.1093/brain/aww250.

S41. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: A cross-sectional analysis. Lancet Neurol. 2015;14(3):253-262. doi:10.1016/S1474-4422(14)70324-2

S42. Boeve B, Bove J, Brannelly P, et al. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. In: Alzheimer's and Dementia. Vol 16. John Wiley and Sons Inc.; 2020:22-36. doi:10.1016/j.jalz.2019.06.4947

S43. Rosen HJ, Boeve BF, Boxer AL. Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimer's Dement. 2020;16(1):71-78. doi:10.1002/alz.12004

S44. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020;19(2):145-156. doi:10.1016/S1474-4422(19)30394-1

S45. Otto M, Ludolph AC, Landwehrmeyer B, et al. Konsortium zur Erforschung der frontotemporalen Lobärdegeneration. Nervenarzt. 2011;82(8):1002-1005. doi:10.1007/s00115-011-3261-3

S46. DZNE DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders) > DESCRIBE-FTD (DZNE - Clinical Registry Study on Frontotemporal Dementia (FTD)). Accessed July 29, 2020. https://www.dzne.de/en/research/studies/clinical-studies/describe/describe-ftd

S47. Jabbari E, Holland N, Chelban V, et al. Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol. 2020;77(3):377-387. doi:10.1001/jamaneurol.2019.4347

S48. 4 repeat tauopathy neuroimaging initiative. Accessed July 29, 2020. http://4rtni-ftldni.ini.usc.edu/

S49. Galimberti D, Fumagalli GG, Fenoglio C, et al. Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiol Aging. 2018;62:245.e9-245.e12. doi:10.1016/j.neurobiolaging.2017.10.016

S50. Meeter LHH, Gendron TF, Sias AC, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018;5(5):583-597. doi:10.1002/acn3.559